A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi‐Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De‐Differentiated Chondrosarcoma
This case report is a valuable example of promising emerging systemic therapies for advanced DDCS, where the present standard of care lacks a repertoire of effective therapies.
Authors
- Peter Grimison (ORCID: https://orcid.org/0000-0002-2653-1657)
- Matthew Youssef
Institutions
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- Chris O’Brien Lifehouse (AU)
Publication Details
- Journal
- Cancer Reports
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1002/cnr2.70426
- Citations
- 1
- Primary Topic
- Bone Tumor Diagnosis and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 46.80